Delphi panel for consensus on the optimal management of dabrafenib plus trametinib-related pyrexia in patients with melanoma

PURPOSE: Dabrafenib and trametinib combination therapy (dab + tram) is indicated to treat BRAF V600 mutation–positive unresectable/metastatic melanoma and as adjuvant treatment for resected stage III disease. Dab + tram–related pyrexia may require early therapy discontinuation. A modified Delphi pan...

Descripción completa

Detalles Bibliográficos
Autores principales: Frazer, Ricky, Gupta, Avinash, Herbert, Christopher, Payne, Miranda, Diaz-Mendoza, Sergio, Vincent, Sally-Anne, Kovaleva, Elena
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9629565/
https://www.ncbi.nlm.nih.gov/pubmed/36339928
http://dx.doi.org/10.1177/17588359221127681

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9629565/
https://www.ncbi.nlm.nih.gov/pubmed/36339928
http://dx.doi.org/10.1177/17588359221127681

Ejemplares similares